Precision medicine start-up Vesynta has become the first medtech company to move into a laboratory at south London’s latest incubator space.
The company, which was spun out from the Adaptive and Responsive Nanomaterials group at University College London, has moved into the Innovation Gateway at The London Cancer Hub in Sutton. The start-up is developing a technology platform to support personalised dosing.
Vesynta’s platform will measure how much of a therapeutic drug stays in the body of a patient, and for how long. This medicine exposure is used to predict dose adjustments that are personalised to the patient, with the aim of improving outcomes and reducing treatment-related side effects.
The company is currently working with the National Institute of Health and Care Research (NIHR)-funded ChromaDose programme, which aims to optimise dosing of anthracycline chemotherapies for children with cancer.
Vesynta now aims to work with experts in cancer pharmacology, precision medicine and data science who are already based at The London Cancer Hub.
Vesynta takes its place alongside physiotherapy company The Exercise Clinic as one of the first companies to take space in the laboratories and collaborative building at the centre of The London Cancer Hub.
The London Cancer hub is hoping to generate 7,000 jobs in the life sciences sector and contribute £1.2 billion each year to the UK’s economy. It is home to the Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust.
Professor Kristian Helin, Chief Executive at The Institute of Cancer Research, London, said: “We’re delighted to welcome Vesynta as part of the first wave of new arrivals to the Innovation Gateway, and it’s a pleasure to see a vibrant collaborative culture already emerging at the centre – involving active discussions and collaborations with researchers here at the ICR and our close colleagues at The Royal Marsden.
“The Innovation Gateway has a unique place in the thriving London life-science ecosystem in having such a strong focus on translating discoveries into having an impact for cancer patients, and we look forward to working with more companies like Vesynta as The London Cancer Hub develops.”
Dr Jugal Suthar, CEO of Vesynta, added: “Being located at The Innovation Gateway is of significant strategic importance to Vesynta, as it integrates our commercial development into a rich ecosystem of clinical and academic researchers who are the key opinion leaders in their field. Our proximity to world renowned institutions will help with our ambitions to strengthen our ties with The Royal Marsden and establish new collaborations with The Institute of Cancer Research in existing and novel areas.”